Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 5, 2012, Pages 635-645

  Zhang, Hongyong ^a   Aina, Olulanu H ^a   Lam, Kit S ^a   de Vere White, Ralph ^b   Evans, Christopher ^b   Henderson, Paul ^a   Lara, Primo N ^a,b,c   Wang, Xiaobing ^d   Bassuk, James A ^e   Pan, Chong xian ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^d AnaSpec Inc   (United States)

^e SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Bladder cancer; Combinatorial chemistry; Targeted therapy

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; FLUORESCENT DYE; GLUTAMYLASPARTYLGLYCYLARGYLMETHYLGLYCYLPHENYLALANINE; PLZ 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; BINDING AFFINITY; BLOOD CELL; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CELL SUSPENSION; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG SPECIFICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FIBROBLAST; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; SINGLE CELL SUSPENSION; TRANSITIONAL CELL CARCINOMA; TUMOR XENOGRAFT; URINALYSIS; WHOLE CELL BINDING ASSAY;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CARBOCYANINES; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; COMBINATORIAL CHEMISTRY TECHNIQUES; FEMALE; HUMANS; JURKAT CELLS; LIGANDS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASMS, EXPERIMENTAL; PEPTIDE LIBRARY; PEPTIDES; PEPTIDES, CYCLIC; PROTEIN BINDING; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 84866769966     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.06.011     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Fleming J.D., Cooper J.S., Jenson D.E., et al. AJCC (American Joint Committee on Cancer) Cancer Staging Manuel 1997, Lippincott-Raven, Philadelphia. 5th ed.
3. Herr H.W., Schwalb D.M., Zhang Z.F., et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: 10-Year follow-up of a prospective randomized trial. J Clin Oncol 1995, 13:1404-1408.
4. Herr H.W., Badalament R.A., Amato D.A., et al. Superficial bladder cancer treated with bacillus Calmette-Guerin: A multivariate analysis of factors affecting tumor progression. J Urol 1989, 141:22-29.
5. Cookson M.S., Herr H.W., Zhang Z.F., et al. The treated natural history of high risk superficial bladder cancer: 15-Year outcome. J Urol 1997, 158:62-67.
6. Eissa S., Kassim S., El-Ahmady O. Detection of bladder tumours: Role of cytology, morphology-based assays, biochemical and molecular markers. Curr Opin Obstet Gynecol 2003, 15:395-403.
7. van Rhijn B.W., van der Poel H.G., van der Kwast T.H. Urine markers for bladder cancer surveillance: A systematic review. Eur Urol 2005, 47:736-748.
8. Lotan Y., Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology 2003, 61:109-118. Discussion 118.
9. Riley G.F., Potosky A.L., Lubitz J.D., et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995, 33:828-841.
10. Botteman M.F., Pashos C.L., Redaelli A., et al. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 2003, 21:1315-1330.
11. Lee S.M., Lee E.J., Hong H.Y., et al. Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol Cancer Res 2007, 5:11-19.
12. Lam K.S., Salmon S.E., Hersh E.M., et al. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 1991, 354:82-84.
13. Lam K.S., Lebl M., Krchnak V. The "one-bead-one-compound" combinatorial library method. Chem Rev 1997, 97:411-448.
14. Songyang Z., Margolis B., Chaudhuri M., et al. The phosphotyrosine interaction domain of SHC recognizes tyrosine-phosphorylated NPXY motif. J Biol Chem 1995, 270:14863-14866.
15. Liu R., Marik J., Lam K.S. A novel peptide-based encoding system for "one-bead one-compound" peptidomimetic and small molecule combinatorial libraries. J Am Chem Soc 2002, 124:7678-7680.
16. Peng L., Liu R., Marik J., et al. Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging. Nat Chem Biol 2006, 2:381-389.
17. Bagai S., Rubio E., Cheng J.F., et al. Fibroblast growth factor-10 is a mitogen for urothelial cells. J Biol Chem 2002, 277:23828-23837.
18. Luo J., Zhang H., Xiao W. Rainbow beads: A color coding method to facilitate high-throughput screening and optimization of one-bead one-compound combinatorial libraries. J Comb Chem 2008, 10:599-604.
19. Drieskens O., Oyen R., Van Poppel H., et al. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005, 32:1412-1417.
20. Liu I.J., Lai Y.H., Espiritu J.I., et al. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int 2006, 77:69-75.
21. Herr H.W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005, 174:2134-2137.
22. Daniltchenko D.I., Riedl C.R., Sachs M.D., et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-Year results of a prospective randomized study. J Urol 2005, 174:2129-2133. Discussion 2133.
23. Grossman H.B. Does fluorescence cystoscopy improve the outcome of patients with bladder cancer? 2005.
24. Chuman Y., Uren A., Cahill J., et al. Identification of a peptide binding motif for secreted frizzled-related protein-1. Peptides 2004, 25:1831-1838.
25. Koivunen E., Gay D.A., Ruoslahti E. Selection of peptides binding to the α5β1 integrin from phage display library. J Biol Chem 1993, 268:20205-20210.
26. Koivunen E., Wang B., Ruoslahti E. Isolation of a highly specific ligand for the α5β1 integrin from a phage display library. J Cell Biol 1994, 124:373-380.
27. Asokan A., Hamra J.B., Govindasamy L., et al. Adeno-associated virus type 2 contains an integrin α5β1 binding domain essential for viral cell entry. J Virol 2006, 80:8961-8969.
28. Morini M., Mottolese M., Ferrari N., et al. The α3β1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000, 87:336-342.
29. Wang S., Chen K.J., Wu T.H., et al. Photothermal effects of supramolecularly assembled gold nanoparticles for the targeted treatment of cancer cells. Angew Chem Int Ed Engl 2010, 49:3777-3781.
30. Litynska A., Przybylo M., Ksiazek D., et al. Differences of α3β1 integrin glycans from different human bladder cell lines. Acta Biochim Pol 2000, 47:427-434.